This is Updates at Antiverse
Welcome to our blog platform! Here, we post our pivotal updates on our progress, news and press releases, as well as a series of written content by our team on topics within drug discovery and artificial intelligence in biotechnology and pharmaceuticals.
Subscribe to Updates at Antiverse!
Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to curate diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.
To learn more about Antiverse and how we are engineering the future of drug discovery, you can visit our website antiverse.io and follow us on LinkedIn and Twitter.